Navigation Links
VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
Date:4/3/2009

SAN FRANCISCO, April 3 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it has received a letter, dated March 31, 2009, from the staff of the NASDAQ Stock Market informing the Company that it does not currently comply with NASDAQ Marketplace Rule 4310(c)(3). NASDAQ Marketplace Rule 4310(c)(3) requires companies maintain either: (i) $2,500,000 in stockholders' equity; (ii) a market value of listed securities of $35,000,000; or (iii) net income from continuing operations of $500,000 in the most recently completed fiscal year or two of the last three most recently completed fiscal years. The Company intends to submit a specific plan to achieve and sustain compliance with the $2,500,000 stockholders' equity standard by April 15, 2009, including the time frame for completion of the compliance plan. If the NASDAQ staff determines that the Company's plan does not adequately address the issue noted above, the NASDAQ staff will provide written notice that the Company's securities will be delisted. At that time, the Company may appeal the NASDAQ staff's determination to a NASDAQ Listing Qualifications Panel (the "Panel"), which would stay any further delisting action by NASDAQ pending a final decision by the Panel. No assurances can be provided that NASDAQ will grant the Company sufficient time to execute its plan to insure that it will maintain its NASDAQ listing.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
2. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
3. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
4. NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
5. Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
6. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
7. VIA Pharmaceuticals to Present Poster at AHA Arteriosclerosis, Thrombosis and Vascular Biology Conference 2009
8. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
9. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
10. Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors
11. VIA Pharmaceuticals Complies With NASDAQ Rules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... August 29, 2014 Three Lawrence ... 2014 Hydrogen Production R&D Award for ... splitting water using sunlight. , Shared with collaborators ... the University of Nevada, Las Vegas (UNLV), the ... models of photoelectrochemical solar-hydrogen production and corrosion processes. ...
(Date:8/29/2014)... 29, 2014 A major challenge before ... start-up dense realm of Boston-Cambridge, is gaining visibility that ... James Sherley, the Director of Boston’s Adult Stem Cell ... and national visibility of his company an important priority ... In addition to a social media marketing campaign ...
(Date:8/28/2014)... USA (PRWEB) August 28, 2014 SPIE ... of Physics and Optical Science and Director of the ... of North Carolina at Charlotte, and co-founder and Chairman ... to serve as the 2015 Vice President of SPIE, ... 2014 President Philip Stahl announced recent election results at ...
(Date:8/28/2014)... August 28, 2014 Best Sanitizers, Inc., ... an alcohol-based hand sanitizer, asks food processors and food ... the hand sanitizer they’re currently using to Best Sanitizers’ ... hygiene is critical to fighting cross-contamination and the spread ... Sanitizers believes there are key criteria that make a ...
Breaking Biology Technology:Livermore Team Awarded for Hydrogen Production Research 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3
... (Nasdaq: NPSP ) announced today that it ... decision whether to,proceed with ex-U.S. development and commercialization ... expects to receive,notification from Nycomed at the end ... NPS on the development of GATTEX(TM) (teduglutide),outside North ...
... presented at AACR-NCI-EORTC International Conference on ... and Cancer Therapeutics in San Francisco, ... Zentaris Inc.,(TSX: AEZ; Nasdaq: AEZS), a global ... today presented an abstract outlining novel,data generated ...
... antibody uses novel approach to "de-cloak" cancers -, ... Inc., (TSX:,ARI), a biotechnology company discovering and developing ... new findings have been,presented from its Trop-2 and ... Trop-2 and CD59 abstracts at the AACR press,conference ...
Cached Biology Technology:NPS Pharmaceuticals to Report Third Quarter 2007 Financial Results and Nycomed Decision on GATTEX(TM) Partnership on November 1, 2007 2AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment 2AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment 3AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment 4Arius announces new findings in Trop-2 and CD59 CANCER antibody programs 2Arius announces new findings in Trop-2 and CD59 CANCER antibody programs 3
(Date:9/1/2014)... Is television making us fat? An increasing amount of ... food consumption and a more sedentary lifestyle. Now, a ... TV is alike. Some TV programs might lead people ... find that if you,re watching an action movie while ... Aner Tal, Ph.D. lead author on the new article ...
(Date:9/1/2014)... birth, every child in the U.S. undergoes a battery ... including sickle cell disease. Thousands of children born in ... suffer and die from the disease each year. ... at least some of those deaths. , A ... the lab of George Whitesides, the Woodford L. and ...
(Date:9/1/2014)... As nocturnal animals, bats are perfectly adapted to a life ... between the reflected echoes to measure distance to obstacles or ... different echo delays. A study carried out by researchers at ... that this map dynamically adapts to external factors. , ... bat flies in too close to an object, the number ...
Breaking Biology News(10 mins):Can action movies make you fat? 2Faster, cheaper tests for sickle cell 2Faster, cheaper tests for sickle cell 3Zooming in for a safe flight 2
... Sciences, The Pennsylvania State University, State College, Pennsylvania, 12-15 August ... 2012 -- The Society for the Study of Reproduction ... the 45th SSR Annual Meeting to be held in State ... are to be found on the SSR Meeting page ...
... is available in Spanish . The upsurge ... and affects crops in particular. However, Anabel Robredo, a biologist at ... the case of barley at least, climate change itself is providing ... change is in fact also responsible for a considerable increase in ...
... ANGELES (Jan. 25, 2012) The evolutionary processes ... debate. John Torday, Ph.D., a lead investigator ... has recently co-authored a book entitled Evolutionary Biology, ... biology into evolutionary biology. Rather than focusing ...
Cached Biology News:Barley adapts to climate change 2Barley adapts to climate change 3LA BioMed's Dr. John Torday examines evolution from a cellular perspective 2
... The H2OBIT™ is a fully licensed, high throughput, ... processing of up to 24 microplates. This equates ... plates. A robotic arm rapidly transfers ... resulting in temperature ramping times that are considerably ...
... ONE Ribonuclease is a 27kDa periplasmic enzyme ... of RNA to cyclic nucleotide monophosphate (NMP) ... of these intermediates to 3-NMPs (1). RNase ... known RNases that can cleave a phosophodiester ...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
...
Biology Products: